Allergy Immunotherapy Tablet

FDA Allergenic Committee Will Meet to Discuss Bla for Ragweed Sublingual AIT Tablet
Dec 30, 2013
Denmark-based pharmaceutical company ALK-Abello has announced that the FDA Allergenic Products Advisory Committee of the US Food and Drug Administration (FDA) will meet on 28 January 2014 to discuss the biologic license application (BLA) ...

Tags: Allergy Tablet, FDA Advisory Committee
FDA Acceptance of Biologics License Application Sublingual Allergy Immunotherapy Tablet
May 13, 2013
Merck, referred to as MSD outside the US and Canada, has announced the FDA acceptance of biologics license application (BLA) of investigational ragweed pollen (Ambrosia artemisiifolia) sublingual allergy immunotherapy tablet for review. ...

Tags: Merck Biologics, Medicine
The US FDA Has Accepted Merck's BLA for an Investigational AIT
Mar 28, 2013
The US FDA has accepted Merck's biologics license application (BLA) for an investigational allergy immunotherapy tablet (AIT), Timothy grass pollen (Phleum pratense). The application includes safety and efficacy data of the ...

Tags: FDA, Merck Bla, Allergy Immunotherapy Tablet